摘要
目的观察阿德福韦酯联合复方牛胎肝提取物治疗慢性乙型肝炎肝硬化失代偿期患者的疗效和安全性。方法选择HBsAg、HBeAb和HBcAb阳性（10^3copies／ml〈HBV—DNA〈10^6copies／ml）的肝硬化失代偿期患者45例。随机分为两组，一组采用普通保肝对症治疗加用阿德福韦酯抗病毒治疗，另一组在保肝对症治疗的基础上加用阿德福韦酯联合复方牛胎肝提取物抗病毒抗纤维化治疗。结果治疗前两组各项指标差异无统计学意义，而治疗6个月后与治疗前比较，差异均有统计学意义，其中，ALT复常率、HBV—DNA转阴率（〈10^3copies／m1）治疗组分别为75．0％（1S／24），45．8％（11／24），对照组分别为76．1％（16／21），42．8％（9／21），两组差异均无统计学意义（P〉0．05）。两组血清HA、LN和PC3均下降，两组间差异有统计学意义（P〈0.05）。治疗组临床症状明显改善的患者比例是87．5％（21／24），显著高于对照组的52．4％（11／21）（P〈0．05）。未观察到明显不良反应。结论阿德福韦酯联合复方牛胎肝提取物治疗肝硬化失代偿期间患者的疗效肯定，安全性好。
Objective To observe the effects and safety of adefovir combined with anfate （compound fetal cow hver extract tablets）in treament of patients with decompensated cirrhosis caused by chronic hepatitis B.Methods 45 decompensated cirrhosis patients with HBsAg, HBeAb-P＆itive ttBcAb-Positive （ 103 Copies/ml 〈 HBV-DNA Level 〈 10＂6 Copies/ml）were randomly divided into conventional therapy group and with adefovie Combined An/ate Aapsule treatment. The clinical effectiveness after 6months was observed. Results The rates of serum ALT normalization, HBV-DNA levels undetectable（ 〈 103copies/ml） ,were 75.0% （18/24） ,g5.8% （11/24）. in adefovie combined An- fate treatment group and 76.1% （ 16/21 ） ,42.8% （9/21） in control group,there was no statistically significant differ- ence between the two groups after 6months（ P 〉 0.05 ）. Hepatic fibrosis index as HA, LN,PC3 were decreased in two groups. There was respectively between the two groups, ,in the therapy group the rate patients got distinct improvement about the clinical symptoms was 87.5% （ 21/24 ）, which was remarkably higher than placebo group＇s 52.4% （ 11/21 ）. （ P 〈 0.05 ）. There was no ebidence of renal toxicity. Conclusion The effect of adefovir combined with anfate in treatment of decompensated cirhosis was stable and safe for.
出处
《中国基层医药》
CAS
2011年第17期2354-2356,共3页
Chinese Journal of Primary Medicine and Pharmacy
